



(51) International Patent Classification:

A61K 31/454 (2006.01) C12Q 1/37 (2006.01)

A61K 31/517 (2006.01)

(21) International Application Number:

PCT/US2021/044838

(22) International Filing Date:

05 August 2021 (05.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/061,741 05 August 2020 (05.08.2020) US

63/136,586 12 January 2021 (12.01.2021) US

(71) Applicant: C4 THERAPEUTICS, INC. [US/US]; 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(72) Inventors: HENDERSON, James A.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). NASVESCHUK, Christopher G.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). LAZARSKI, Kiel; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). GARZA, Victoria; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(US). MOUSTAKIM, Moses; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). AHN, Jae Young; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). VEITS, Gesine Kerstin; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). O'SHEA, Morgan Welzel; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). MICHAEL, Ryan E.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). YAP, Jeremy L.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). LIANG, Yanke; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). GOOD, Andrew Charles; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). FITZGERALD, Mark E.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US). YU, Robert T.; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472 (US).

(74) Agent: BELLOWS, Brent R. et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: COMPOUNDS FOR TARGETED DEGRADATION OF RET







FIG. 9

(57) Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*